Overview

Zoptarelin Doxorubicin (AEZS 108) as Second Line Therapy for Endometrial Cancer

Status:
Completed
Trial end date:
2017-01-30
Target enrollment:
Participant gender:
Summary
Open-label, randomized, active-controlled, two-arm Phase III study to compare the efficacy and safety of AEZS-108 and doxorubicin.
Phase:
Phase 3
Details
Lead Sponsor:
AEterna Zentaris
Treatments:
Doxorubicin
Liposomal doxorubicin